Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024.
波士顿，2024年5月14日（GLOBE NEWSWIRE）——Compass Therapeutics, Inc.（纳斯达克股票代码：CMPX）是一家临床阶段、专注于肿瘤学的生物制药公司，开发专有抗体疗法来治疗多种人类疾病，今天宣布，该公司将参加在H.C. Wainwright 2举行的炉边谈话和 年度生物连接投资者会议将于2024年5月20日在纽约州纽约市举行。
Fireside Chat details
Date: Monday, May 20
Time: 11:30 AM ET
Webcast Link:
炉边聊天详情
日期：5月20日星期一
时间：美国东部时间上午 11:30
网络直播链接：
Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass' Events page.
虚拟/重播可用性：公司演示将在Compass的活动页面上存档90天。
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at .
关于康帕思疗法
Compass Therapeutics, Inc. 是一家以肿瘤学为重点的临床阶段生物制药公司，开发专有的基于抗体的疗法，用于治疗多种人类疾病。Compass 的科学重点是血管生成、免疫系统和肿瘤生长之间的关系。公司的新型候选产品线旨在靶向有效抗肿瘤反应所需的多种关键生物途径。其中包括通过血管生成靶向药物调节微血管，通过肿瘤微环境中效应细胞的激活剂诱导强效免疫反应，以及缓解肿瘤用来逃避免疫监测的免疫抑制机制。康帕思计划通过临床开发来推进其候选产品，既可以作为独立疗法，也可以结合基于支持性临床和非临床数据的专有管道抗体。该公司成立于2014年，总部位于马萨诸塞州波士顿。欲了解更多信息，请访问康帕思疗法网站，网址为。
Investor Contact
ir@compasstherapeutics.com
投资者联系人
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Communications Manager
media@compasstherapeutics.com
617-500-8099
媒体联系人
安娜·吉福德，高级传播经理
media@compasstherapeutics.com
617-500-8099
译文内容由第三方软件翻译。